CAS NO: | 926259-99-6 |
规格: | ≥98% |
包装 | 价格(元) |
10mg | 电议 |
25mg | 电议 |
50mg | 电议 |
100mg | 电议 |
250mg | 电议 |
500mg | 电议 |
1g | 电议 |
Molecular Weight (MW) | 214.22 |
---|---|
Formula | C11H10N4O |
CAS No. | 926259-99-6 |
Storage | -20℃ for 3 years in powder form |
-80℃ for 2 years in solvent | |
Solubility (In vitro) | DMSO: 42 mg/mL (196.1 mM) |
Water: <1 mg/mL | |
Ethanol: 2 mg/mL warmed (9.3 mM) | |
Other info | Chemical Name: N-(2-Aminophenyl)pyrazine-2-carboxamide; BG45 InChi Key: LMWPVSNHKACEKW-UHFFFAOYSA-N InChi Code: InChI=1S/C11H10N4O/c12-8-3-1-2-4-9(8)15-11(16)10-7-13-5-6-14-10/h1-7H,12H2,(H,15,16) SMILES Code: O=C(C1=NC=CN=C1)NC2=CC=CC=C2N |
Synonyms | BG45; BG-45; BG 45 |
In Vitro | In vitro activity: BG45 causes significant cell growth inhibition and induces caspase-dependent apoptosis in a series of MM cells. In RPMI8226 cells, BG45 synergistically enhances bortezomib-induced cytotoxicity. Cell Assay: The growth inhibitory effects of BG45 in MM cell lines are assessed by measuring 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrasodium bromide (MTT) dye absorbance. To measure proliferation of MM cells, the rate of DNA synthesis is measured by [3H]thymidine uptake. Cell lines: MM.1S, RPMI8226, U266, H929, MM.1 R, RPMI-LR5, OPM1, OPM2 and RPMI-DOX40 cells. |
---|---|
In Vivo | In mice bearing MM.1S xenograft of human MM, BG45 (50 mg/kg, i.p.) significantly inhibits MM tumor growth. When in combination with bortezomib, BG45 (50 mg/kg, i.p.) enhances bortezomib-induced cytotoxicity. |
Animal model | Mice bearing MM.1S xenograft |
Formulation & Dosage | Dissolved in 10% dimethylacetamide in 10% Kolliphor HS15 in PBS; 50 mg/kg, 5 days a week; i.p. injection |
References | Leukemia. 2014 Mar;28(3):680-9. |